Clareo Health | Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Noven Therapeutics
With
Noven Pharmaceuticals, Inc.
Attention-Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder characterized by 3 main symptoms: inattention, hyperactivity and impulsivity. This study will assess the safety and tolerability of SPD485 while attempting to establish the appropriate starting dose for subjects previously on an existing long-acting methylphenidate product.
Age
6–12
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject must have a primary diagnosis of ADHD
Subject must be adequately controlled on a stable dose of one of the following medications for a 30 day period: Ritalin LA(r), Concerta(r), or Metadate DC(r), not to exceed 54 mg per day
Females of childbearing potential must have a negative serum beta Human Chorionic Gonadotropin pregnancy test
You may not be if
A history of mental retardation that would indicate that the subject is not functioning at an age appropriate level intellectually
A recent history of suspected substance abuse or dependence disorder
Subject is taking Strattera
Clinical signs and symptoms of skin irritation or hyper/hypopigmentation at the potential application sites
